Loading...
Bandhan BSE Healthcare Index Fund Direct Growth
EquityIndex FundsVery High Risk
Direct
NAV (21-Nov-24)
₹9.740.11%1D
Returns (Since Inception)
-2.57%
Rated ★4.5+ on 
Fund Overview
Fund Size
₹18 Cr
Expense Ratio
0.22%
ISIN
INF194KB1IS2
Minimum SIP
₹1,000
Exit Load
No Charges
Inception Date
06 Sep 2024
About this fund
This fund has been in existence for 2 months and 16 days, having been launched on 06-Sep-24.
As of 21-Nov-24, it has a Net Asset Value (NAV) of ₹9.74, Assets Under Management (AUM) of 17.62 Crores, and an expense ratio of 0.22%.
As of 21-Nov-24, it has a Net Asset Value (NAV) of ₹9.74, Assets Under Management (AUM) of 17.62 Crores, and an expense ratio of 0.22%.
- Bandhan BSE Healthcare Index Fund Direct Growth has given a CAGR return of -2.57% since inception.
- The fund's asset allocation comprises around 100.06% in equities, 0.00% in debts, and -0.06% in cash & cash equivalents.
- You can start investing in Bandhan BSE Healthcare Index Fund Direct Growth with a SIP of ₹1000 or a Lumpsum investment of ₹1000.
Performance against Category Average
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
Since Inception
-2.57%
— (Cat Avg.)
Portfolio Summaryas of 31st October 2024
| Equity | ₹17.63 Cr | 100.06% |
| Others | ₹-0.01 Cr | -0.06% |
Top Holdings
All Holdings
Equity
Debt & Others
| Name | Type  | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹2.72 Cr | 15.45% |
| Cipla Ltd | Equity | ₹1.18 Cr | 6.70% |
| Dr Reddy's Laboratories Ltd | Equity | ₹1.06 Cr | 6.01% |
| Divi's Laboratories Ltd | Equity | ₹1.02 Cr | 5.81% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹1.02 Cr | 5.81% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹0.95 Cr | 5.41% |
| Lupin Ltd | Equity | ₹0.72 Cr | 4.09% |
| Aurobindo Pharma Ltd | Equity | ₹0.54 Cr | 3.04% |
| Fortis Healthcare Ltd | Equity | ₹0.44 Cr | 2.52% |
| Alkem Laboratories Ltd | Equity | ₹0.41 Cr | 2.35% |
| Torrent Pharmaceuticals Ltd | Equity | ₹0.4 Cr | 2.26% |
| Mankind Pharma Ltd | Equity | ₹0.36 Cr | 2.07% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹0.35 Cr | 1.96% |
| Zydus Lifesciences Ltd | Equity | ₹0.34 Cr | 1.95% |
| Ipca Laboratories Ltd | Equity | ₹0.29 Cr | 1.65% |
| Laurus Labs Ltd | Equity | ₹0.26 Cr | 1.50% |
| Suven Pharmaceuticals Ltd | Equity | ₹0.23 Cr | 1.30% |
| Piramal Pharma Ltd | Equity | ₹0.22 Cr | 1.27% |
| Syngene International Ltd | Equity | ₹0.21 Cr | 1.21% |
| Abbott India Ltd | Equity | ₹0.21 Cr | 1.18% |
| Biocon Ltd | Equity | ₹0.19 Cr | 1.09% |
| J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹0.19 Cr | 1.08% |
| Krishna Institute of Medical Sciences Ltd | Equity | ₹0.18 Cr | 1.03% |
| Gland Pharma Ltd | Equity | ₹0.18 Cr | 1.01% |
| Ajanta Pharma Ltd | Equity | ₹0.18 Cr | 1.01% |
| Natco Pharma Ltd | Equity | ₹0.17 Cr | 0.97% |
| Neuland Laboratories Limited | Equity | ₹0.17 Cr | 0.97% |
| Dr. Lal PathLabs Ltd | Equity | ₹0.16 Cr | 0.89% |
| GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹0.15 Cr | 0.86% |
| Concord Biotech Ltd | Equity | ₹0.15 Cr | 0.83% |
| Strides Pharma Science Ltd | Equity | ₹0.14 Cr | 0.82% |
| Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹0.14 Cr | 0.77% |
| Poly Medicure Ltd | Equity | ₹0.14 Cr | 0.77% |
| Global Health Ltd | Equity | ₹0.13 Cr | 0.71% |
| Jubilant Pharmova Ltd | Equity | ₹0.12 Cr | 0.70% |
| Wockhardt Ltd | Equity | ₹0.12 Cr | 0.69% |
| Narayana Hrudayalaya Ltd | Equity | ₹0.12 Cr | 0.66% |
| Granules India Ltd | Equity | ₹0.11 Cr | 0.64% |
| Rainbow Childrens Medicare Ltd | Equity | ₹0.11 Cr | 0.63% |
| Pfizer Ltd | Equity | ₹0.11 Cr | 0.60% |
| Eris Lifesciences Ltd Registered Shs | Equity | ₹0.09 Cr | 0.49% |
| Alembic Pharmaceuticals Ltd | Equity | ₹0.08 Cr | 0.48% |
| Sanofi India Ltd | Equity | ₹0.08 Cr | 0.47% |
| Marksans Pharma Ltd | Equity | ₹0.08 Cr | 0.46% |
| Metropolis Healthcare Ltd | Equity | ₹0.07 Cr | 0.43% |
| Jupiter Life Line Hospitals Ltd | Equity | ₹0.07 Cr | 0.39% |
| AstraZeneca Pharma India Ltd | Equity | ₹0.06 Cr | 0.37% |
| Vijaya Diagnostic Centre Ltd | Equity | ₹0.06 Cr | 0.36% |
| Ami Organics Ltd | Equity | ₹0.06 Cr | 0.36% |
| Shilpa Medicare Ltd | Equity | ₹0.06 Cr | 0.35% |
| Procter & Gamble Health Ltd | Equity | ₹0.06 Cr | 0.32% |
| Caplin Point Laboratories Ltd | Equity | ₹0.06 Cr | 0.32% |
| Glenmark Life Sciences Ltd | Equity | ₹0.04 Cr | 0.25% |
| Aarti Pharmalabs Ltd | Equity | ₹0.04 Cr | 0.24% |
| Net Current Assets | Cash | ₹-0.04 Cr | 0.23% |
| Morepen Laboratories Ltd | Equity | ₹0.04 Cr | 0.21% |
| FDC Ltd | Equity | ₹0.04 Cr | 0.21% |
| Indegene Ltd | Equity | ₹0.03 Cr | 0.20% |
| Kovai Medical Center & Hospital Ltd | Equity | ₹0.03 Cr | 0.20% |
| Advanced Enzyme Technologies Ltd | Equity | ₹0.03 Cr | 0.18% |
| Orchid Pharma Ltd | Equity | ₹0.03 Cr | 0.17% |
| Sun Pharma Advanced Research Co Ltd | Equity | ₹0.03 Cr | 0.17% |
| Triparty Repo Trp_041124 | Cash - Repurchase Agreement | ₹0.03 Cr | 0.17% |
| Sequent Scientific Ltd | Equity | ₹0.03 Cr | 0.17% |
| Solara Active Pharma Sciences Ltd Ordinary Shares | Equity | ₹0.03 Cr | 0.16% |
| Yatharth Hospital and Trauma Care Services Ltd | Equity | ₹0.03 Cr | 0.14% |
| HealthCare Global Enterprises Ltd | Equity | ₹0.02 Cr | 0.14% |
| Indraprastha Medical Corp Ltd | Equity | ₹0.02 Cr | 0.14% |
| Krsnaa Diagnostics Ltd | Equity | ₹0.02 Cr | 0.13% |
| Unichem Laboratories Ltd | Equity | ₹0.02 Cr | 0.13% |
| Aarti Drugs Ltd | Equity | ₹0.02 Cr | 0.13% |
| Supriya Lifescience Ltd | Equity | ₹0.02 Cr | 0.12% |
| Hikal Ltd | Equity | ₹0.02 Cr | 0.11% |
| Thyrocare Technologies Ltd | Equity | ₹0.02 Cr | 0.11% |
| Dishman Carbogen Amics Ltd | Equity | ₹0.02 Cr | 0.10% |
| Innova Captab Ltd | Equity | ₹0.02 Cr | 0.09% |
| Gufic Biosciences Ltd | Equity | ₹0.02 Cr | 0.09% |
| Blue Jet Healthcare Ltd | Equity | ₹0.02 Cr | 0.09% |
| Indoco Remedies Ltd | Equity | ₹0.02 Cr | 0.09% |
| RPG Life Sciences Ltd | Equity | ₹0.01 Cr | 0.08% |
| IOL Chemicals And Pharmaceuticals Ltd | Equity | ₹0.01 Cr | 0.07% |
| Syncom Formulation (India) Ltd | Equity | ₹0.01 Cr | 0.07% |
| Hester Biosciences Ltd | Equity | ₹0.01 Cr | 0.07% |
| Gujarat Themis Biosyn Ltd | Equity | ₹0.01 Cr | 0.07% |
| SMS Pharmaceuticals Ltd | Equity | ₹0.01 Cr | 0.07% |
| Windlas Biotech Ltd | Equity | ₹0.01 Cr | 0.07% |
| Bliss GVS Pharma Ltd | Equity | ₹0.01 Cr | 0.06% |
| Artemis Medicare Services Ltd Ordinary Shares | Equity | ₹0.01 Cr | 0.06% |
| Suven Life Sciences Ltd | Equity | ₹0.01 Cr | 0.06% |
| Kopran Ltd | Equity | ₹0.01 Cr | 0.06% |
| Sigachi Industries Ltd | Equity | ₹0.01 Cr | 0.06% |
| Themis Medicare Ltd | Equity | ₹0.01 Cr | 0.06% |
| Novartis India Ltd | Equity | ₹0.01 Cr | 0.06% |
| Shalby Ltd | Equity | ₹0.01 Cr | 0.05% |
| Lincoln Pharmaceuticals Ltd | Equity | ₹0.01 Cr | 0.05% |
| Tarsons Products Ltd | Equity | ₹0.01 Cr | 0.05% |
| GPT Healthcare Ltd | Equity | ₹0.01 Cr | 0.04% |
| Vimta Labs Ltd | Equity | ₹0.01 Cr | 0.03% |
| NGL Fine-Chem Ltd | Equity | ₹0 Cr | 0.03% |
| KMC Speciality Hospitals (India) Ltd | Equity | ₹0 Cr | 0.02% |
| Sastasundar Ventures Ltd | Equity | ₹0 Cr | 0.02% |
| Cash Margin - Ccil | Cash - Repurchase Agreement | ₹0 Cr | 0.00% |
Allocation By Market Cap (Equity)
Large Cap Stocks
45.66%
Mid Cap Stocks
28.50%
Small Cap Stocks
24.93%
Other Allocation
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹17.36 Cr | 98.55% |
| Basic Materials | ₹0.1 Cr | 0.54% |
Risk & Performance Ratios
Standard Deviation
This fund
--
Cat. avg.
--
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
--
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
--
Higher the better
Fund Managers
Nemish Sheth
Since September 2024
Additional Scheme Detailsas of 31st October 2024
ISIN INF194KB1IS2 | Expense Ratio 0.22% | Exit Load No Charges | Fund Size ₹18 Cr | Age 2 months | Lumpsum Minimum ₹1,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
Investment Objective
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Tax Treatment
Capital Gains Taxation:
Dividend Taxation:
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Similar Index Funds Funds
| Fund name | Expense Ratio | Exit Load | Fund size | 1Y  |
|---|---|---|---|---|
| ICICI Prudential Nifty Midcap 150 Index Fund Direct Growth Very High Risk | 0.3% | 0.0% | ₹565.80 Cr | 29.4% |
| ICICI Prudential Nifty Midcap 150 Index Fund Regular Growth Very High Risk | 0.9% | 0.0% | ₹565.80 Cr | 28.7% |
| ICICI Prudential Nifty 200 Momentum 30 Index Fund Regular Growth Very High Risk | 1.0% | 0.0% | ₹471.41 Cr | 33.6% |
| SBI Nifty Midcap 150 Index Fund Regular Growth Very High Risk | 1.0% | 0.0% | ₹670.31 Cr | 28.8% |
| DSP Nifty 50 Equal Weight Index Fund Regular Growth Very High Risk | 0.9% | 0.0% | ₹1886.93 Cr | 20.2% |
| SBI Nifty Smallcap 250 Index Fund Direct Growth Very High Risk | 0.4% | 0.0% | ₹1190.98 Cr | 28.6% |
| SBI Nifty Midcap 150 Index Fund Direct Growth Very High Risk | 0.4% | 0.0% | ₹670.31 Cr | 29.5% |
| ICICI Prudential Nifty 200 Momentum 30 Index Fund Direct Growth Very High Risk | 0.4% | 0.0% | ₹471.41 Cr | 34.3% |
| DSP Nifty 50 Equal Weight Index Fund Direct Growth Very High Risk | 0.4% | 0.0% | ₹1886.93 Cr | 20.9% |
| SBI Nifty Smallcap 250 Index Fund Regular Growth Very High Risk | 1.0% | 0.0% | ₹1190.98 Cr | 27.8% |
Risk Level
Your principal amount will be at Very High Risk
Unlock Expert Insights!
Related Articles
Still got questions?
We're here to help.
What is the current NAV of Bandhan BSE Healthcare Index Fund Direct Growth?
The NAV of Bandhan BSE Healthcare Index Fund Direct Growth, as of 21-Nov-2024, is ₹9.74.
What is the portfolio composition of Bandhan BSE Healthcare Index Fund Direct Growth?
The fund's allocation of assets is distributed as 100.06% in equities, 0.00% in bonds, and -0.06% in cash and cash equivalents.
Who manages the Bandhan BSE Healthcare Index Fund Direct Growth?
The fund managers responsible for Bandhan BSE Healthcare Index Fund Direct Growth are:-
- Nemish Sheth
Disclaimer: Mutual Fund investments are subject to market risks, read all scheme-related documents carefully. The NAVs of the schemes may go up or down depending upon the factors and forces affecting the securities market including the fluctuations in the interest rates. The past performance of the mutual funds is not necessarily indicative of the future performance of the schemes. Investors are requested to review the prospectus carefully and obtain expert professional advice with regard to specific legal, tax and financial implications of the investment/participation in the scheme.
Trending Mutual Funds Searches
Popular Equity Funds
Popular Debt Funds
©2021-2024 Dezerv. All Rights Reserved
Dezerv Investments Private Limited is a Portfolio Manager with SEBI Registration no. INP000007377, a member of BSE with SEBI Stock Broker Registration no. INZ000303136, and an Investment Manager to Category - I AIF-VCF-Angel Fund with SEBI Registration no. IN/AIF1/22-23/1066.
Mutual Fund distribution services are offered through Dezerv Distribution Services Pvt Limited, a wholly owned subsidiary with AMFI Registration No.: ARN -248439. **Mutual fund investments are subject to market risks, read all scheme related documents carefully.** Terms and conditions of the website are applicable. Privacy policy of the website is applicable.
Dezerv Investments Private Limited is a Portfolio Manager with SEBI Registration no. INP000007377, a member of BSE with SEBI Stock Broker Registration no. INZ000303136, and an Investment Manager to Category - I AIF-VCF-Angel Fund with SEBI Registration no. IN/AIF1/22-23/1066.
Mutual Fund distribution services are offered through Dezerv Distribution Services Pvt Limited, a wholly owned subsidiary with AMFI Registration No.: ARN -248439. **Mutual fund investments are subject to market risks, read all scheme related documents carefully.** Terms and conditions of the website are applicable. Privacy policy of the website is applicable.